Alterity Therapeutics Limited (PBN) - Total Assets
Based on the latest financial reports, Alterity Therapeutics Limited (PBN) holds total assets worth €56.92 Million EUR (≈ $66.54 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore PBN operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Alterity Therapeutics Limited - Total Assets Trend (2014–2025)
This chart illustrates how Alterity Therapeutics Limited's total assets have evolved over time, based on quarterly financial data. See what is Alterity Therapeutics Limited's book value for net asset value and shareholders' equity analysis.
Alterity Therapeutics Limited - Asset Composition Analysis
Current Asset Composition (June 2025)
Alterity Therapeutics Limited's total assets of €56.92 Million consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 72.0% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Alterity Therapeutics Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PBN market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alterity Therapeutics Limited's current assets represent 99.7% of total assets in 2025, a decrease from 99.8% in 2014.
- Cash Position: Cash and equivalents constituted 72.0% of total assets in 2025, down from 82.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Alterity Therapeutics Limited Competitors by Total Assets
Key competitors of Alterity Therapeutics Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
|
USA | $472.67 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $506.75 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
|
China | CN¥1.84 Billion |
Alterity Therapeutics Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 21.98 | 3.84 | 12.28 |
| Quick Ratio | 21.98 | 3.84 | 12.28 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €54.24 Million | €7.71 Million | €34.33 Million |
Alterity Therapeutics Limited - Advanced Valuation Insights
This section examines the relationship between Alterity Therapeutics Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.96 |
| Latest Market Cap to Assets Ratio | 1.42 |
| Asset Growth Rate (YoY) | 139.4% |
| Total Assets | €46.03 Million |
| Market Capitalization | $65.25 Million USD |
Valuation Analysis
Above Book Valuation: The market values Alterity Therapeutics Limited's assets above their book value (1.42x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Alterity Therapeutics Limited's assets grew by 139.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Alterity Therapeutics Limited (2014–2025)
The table below shows the annual total assets of Alterity Therapeutics Limited from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | €46.03 Million ≈ $53.81 Million |
+139.42% |
| 2024-06-30 | €19.22 Million ≈ $22.47 Million |
-29.63% |
| 2023-06-30 | €27.32 Million ≈ $31.94 Million |
-33.96% |
| 2022-06-30 | €41.36 Million ≈ $48.36 Million |
+23.16% |
| 2021-06-30 | €33.59 Million ≈ $39.27 Million |
+238.99% |
| 2020-06-30 | €9.91 Million ≈ $11.58 Million |
-50.24% |
| 2019-06-30 | €19.91 Million ≈ $23.28 Million |
+6.32% |
| 2018-06-30 | €18.73 Million ≈ $21.89 Million |
-25.93% |
| 2017-06-30 | €25.28 Million ≈ $29.56 Million |
-25.04% |
| 2016-06-30 | €33.73 Million ≈ $39.43 Million |
-19.38% |
| 2015-06-30 | €41.83 Million ≈ $48.91 Million |
+0.46% |
| 2014-06-30 | €41.64 Million ≈ $48.68 Million |
-- |
About Alterity Therapeutics Limited
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II… Read more